Editorial

2017 Eberhard F. Mammen Award Announcements: Part II–Young Investigator Awards

Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹

¹Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital, Westmead, Australia

Semin Thromb Hemost 2018;44:81–88.

Welcome to another of our Eberhard F. Mammen award announcements. As noted previously,^{1–3} Thieme, the publisher of *Seminars in Thrombosis & Hemostasis*, has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen (►Fig. 1), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories; the current award details and conditions are as follows:

- Most popular article awards: Awarded to the authors of the most popular articles published in *Seminars in Thrombosis & Hemostasis*. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, Errata, Letters to the Editor, and Editorials, and previous award winning articles, are excluded from further consideration of these awards, which currently comprise two categories—one for “Open Access” articles, and another for a “General Category.” There are two major cash prizes of US\$1,000 for each category. In addition, winners of the “General Category” awards are granted “open access” status for these articles thereafter.
- Young Investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US \$1,000 are awarded in any given year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation

Fig. 1 Eberhard F. Mammen (1930–2008).

(or as otherwise agreed) for publication in *Seminars in Thrombosis & Hemostasis*. After nominations are received, the awardees are selected by a vote of the Senior Editors of *Seminars in Thrombosis & Hemostasis*. Any potential conflicts of interest are managed by first identifying these, and excluding those with potential conflicts from voting.

Further details of the awards and the award winners are posted online (<<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>>), and previous award winner announcements are also available in print.^{4–16}

Address for correspondence
E. J. Favaloro, PhD, FFSc (RCPA),
Department of Haematology,
Institute of Clinical Pathology and
Medical Research (ICPMR),
Sydney Centres for Thrombosis
and Haemostasis, Westmead
Hospital, Westmead, NSW, 2145,
Australia (e-mail: emmanuel.
favaloro@health.nsw.gov.au).

Issue Theme Extrahemostatic
Functions of Platelets and
Coagulation Factors; Guest
Editors: Roger J. S. Preston, PhD,
and Ton Lisman, PhD.

Copyright © 2018 by Thieme Medical
Publishers, Inc., 333 Seventh Avenue,
New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <https://doi.org/10.1055/s-0038-1625982>.
ISSN 0094-6176.

The winners of the 2017 Eberhard F. Mammen awards for the most popular articles from *Seminars in Thrombosis & Hemostasis* for the period of 2015 to 2016 inclusive were announced in an earlier issue.¹⁶ It is therefore with great pleasure that we would like to announce the winners of the latest round of Young Investigator awards.

As mentioned above, the Young Investigator awards represent winners of the best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. There are additional considerations given that the nominees' presentations are not always seen by all of the possible award nominators, being drawn from the editorial team of the journal. The latest winners are identified below and also listed in ►Table 1. The latest awardees were all derived from the latest ISTH 2017 meeting, held in Berlin in July, 2017. Due to personal conflicts of interest in relation to award nominees, I excluded myself from voting on this occasion.

Laura Franco (►Fig. 2) is a clinical research fellow at the Internal Medicine Department of University of Perugia, Italy. She received her degree in Medicine in 2010 at the School of Medicine of the University of Perugia, Italy. She completed a

Fig. 2 Young Investigator Award winner Laura Franco.

residency in Emergency Medicine and has worked in the internal medicine ward at the Vascular and Emergency Medicine–Stroke Unit Institute, University of Perugia, Italy. Her main interests are hemorrhagic complications associated with anticoagulant therapy and she is involved in national and international research projects in the field of anticoagulant treatment.

Elodie Laridan (►Fig. 3) is currently a PhD student at the Laboratory for Thrombosis Research, Kortrijk, Belgium. After her graduation in 2013 from the University of Leuven in Belgium as a biomedical scientist, she first worked as a clinical assistant at the university hospital in Leuven for a

Table 1 Latest young investigator awardees

Awardee	Current placement	Presentations awarded
Laura Franco	Internal Medicine, University of Perugia, Italy	Mortality in Patients with Intracerebral Hemorrhage Associated with Vitamin K Antagonists, Direct Oral Anticoagulants, Antiplatelets or No Antithrombotic Therapy
Elodie Laridan	Cardiovascular Sciences, Kulak, Belgium	Neutrophil Extracellular Traps in Thrombi from Patients with Acute Ischemic Stroke
Leonardo Pasalic	Haematology, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Australia	Patients with Coronary Artery Disease Have a Pathological P2Y12 Platelet Response with Heightened Procoagulant Platelet Potential
Yvonne Brennan	Clinical Haematology, Westmead Hospital, Australia	Dental Extractions on NOACs without Stopping Therapy (DENTST) Study
Georgia McCaughan	Australian Red Cross Blood Service, Sydney, Australia	Choice of Anticoagulation in the Obese

Fig. 3 Young Investigator Award winner Elodie Laridan.

year. Her combined interests for basic and clinical research made her join the laboratory in Kortrijk in a project focused on neutrophil extracellular traps and their involvement in ischemic stroke.

Leonardo Pasalic (►**Fig. 4**) is a hematopathologist and clinical hematologist, currently placed at the Institute for Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Sydney, Australia. He received his MD in 2004 from the University of New South Wales (UNSW), Australia. He then completed internal medicine and dual laboratory and clinical hematology training at Westmead Hospital. He received his PhD from the Faculty of Medicine, UNSW, Australia, in 2016, for which he investigated various laboratory assays for characterization of pro-coagulant platelets and their role in immunothrombosis. His current clinical focus is on venous thromboembolism and anticoagulants, as well as bleeding disorders. He has continued to pursue his interests in assay development in the field of hemostasis and thrombosis, with particular interest in use of flow cytometry for evaluation of platelet-based biomarkers in clinical diagnostics and translational research.

Yvonne Brennan (►**Fig. 5**) obtained her medical degree from The University of Sydney in 2006, before completing residency and basic physicians training at various tertiary hospitals in Sydney. She is currently in her final year of hematology training with the Royal Australasian College of Physicians (RACP) and the Royal College of Pathologists of Australasia (RCPA). Dr. Brennan is also currently a thrombosis and hemostasis fellow at Westmead Hospital, where she has an outstanding opportunity to pursue her areas of interests, including thrombosis, hemostasis, and obstetric hematology.

Georgia McCaughan (►**Fig. 6**) is a joint RCPA/RACP Haematology Registrar, currently completing a rotation in Transfusion Medicine at the Australian Red Cross Blood Service in

Fig. 5 Young Investigator Award winner Yvonne Brennan.

Sydney. She received her Bachelor of Medicine/Bachelor of Surgery from the University of Sydney in 2011, graduating with the University Medal. Her current research aims to elucidate the most appropriate anticoagulation strategy in the obese, and she is setting up an Australian and New Zealand prospective registry to examine anticoagulant prescribing patterns, drug-specific levels, and clinical outcomes in this patient group. She is also interested in the diagnostic

Fig. 4 Young Investigator Award winner Leonardo Pasalic.

Fig. 6 Young Investigator Award winner Georgia McCaughan.

approach to heparin-induced thrombocytopenia (HIT), in particular the availability of rapid diagnostic assays to assist in clinical decision making. Georgia is a Clinical Associate Lecturer with Sydney Medical School and is actively engaged in medical student teaching.

All award winners were elated to hear that they had been selected to receive an Eberhard F. Mammen Young Investigator Award, and provided the following additional commentary:

"I am honored to be a recipient of the 2017 Eberhard F. Mammen Young Investigator Award. My presentation was on Mortality in Patients with Intracerebral Haemorrhage Associated with Vitamin K Antagonists, Direct Oral Anticoagulants, Antiplatelets or No Antithrombotic Therapy. I sincerely thank the Award Committee as well as my supervisors Drs. Giancarlo Agnelli, Cecilia Becattini, and Maurizio Paciaroni, and all colleagues who have supported me with my research."

- Laura Franco (►Fig. 2)

"I am very honored to have received an Eberhard F. Mammen Young Investigator Award. I deeply appreciate the recognition for my project. This award acknowledges a team effort and the hard work that has been put into the project. Therefore, I would like to thank Prof. De Meyer and my colleagues from the Laboratory for Thrombosis Research for having given me the opportunity to be part of this new research angle to investigate treatments for ischemic stroke."

- Elodie Laridan (►Fig. 3)

"I am incredibly honored to have been selected to receive an Eberhard F. Mammen Young Investigator Award. This award acknowledges our research investigating the role of procoagulant platelets in atherothrombotic disorders. This award would not have come to realisation without a truly collaborative effort and without the contributions of Drs. Edwina Wing-Lun, Jerrett Lau and Heather Campbell. I would like to take this opportunity to acknowledge my supervisor

Dr. Vivien Chen and all my colleagues at Lowy Cancer Research Institute (Sydney, Australia) for their ongoing support and contribution to this work."

- Leonardo Pasalic (►Fig. 4)

"I was thrilled and honored to be a recipient of an Eberhard F. Mammen Young Investigator Award, and to thus be recorded alongside the impressive list of prior award winners. I would like to thank my dental collaborators who have made possible the work for which I was nominated. I feel very fortunate and grateful to have Dr. Jennifer Curnow as my mentor, and also wish to thank the Editor in Chief of STH, Dr. Emmanuel Favaloro, another of my mentors, for this opportunity to shine."

- Yvonne Brennan (►Fig. 5)

"I was extremely honored to receive an Eberhard F. Mammen Young Investigator Award. The project for which I was nominated, and our prospective registry in development, would not have happened without the support and direction of my supervisors Dr. Helen Crowther and Dr. Jennifer Curnow. I would also like to thank Dr. Leonardo Pasalic and Dr. Emmanuel Favaloro for their support and enthusiasm in encouraging me to pursue research in thrombosis and haemostasis."

- Georgia McCaughan (►Fig. 6)

In keeping with previous editorials, I have again reviewed the Young Investigator awardees from previous years as well as the outcome of their subsequent submissions¹⁷⁻⁵⁰ to *Seminars in Thrombosis & Hemostasis*, and as summarized in ►Table 2. I previously mentioned my personal gratification that most of the papers from earlier years have subsequently appeared in several annual top 100 listings.^{9,10,12,14-16} Of further interest, one of these papers actually won one of the Most Popular awards in 2014 (within the Open Access Category) based on

Table 2 Young investigator awardees from previous years

Awardee	Year awarded	Publication arising
Willem M. Lijfering	2009	Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. <i>Semin Thromb Hemost</i> 2011;37(8):885-896
Salley Pels	2009	Pels SG. Current therapies in primary immune thrombocytopenia. <i>Semin Thromb Hemost</i> 2011;37(6):621-630
Adam Cuker	2010	Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. <i>Semin Thromb Hemost</i> 2012;38(1):31-37
Giridhara Rao Jayandharan	2010	Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. <i>Semin Thromb Hemost</i> 2012;38(1):64-78
Timea Szanto	2010	Szántó T, Joutsu-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. <i>Semin Thromb Hemost</i> 2012;38(1):55-63
Birgitta Salmela	2010	Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost</i> 2012;38(1):23-30
Pia Riittaa-Maria Siljander	2010	Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. <i>Semin Thromb Hemost</i> 2012;38(1):102-113.

Table 2 (Continued)

Awardee	Year awarded	Publication arising
Romarc Lacroix	2011	Lacroix R, Dignat-George F. Microparticles: new protagonists in pericellular and intravascular proteolysis. <i>Semin Thromb Hemost</i> 2013;39(1):33–39
Brad McEwen	2011	McEwen BJ, Morel-Kopp MC, Chen W, Tofter GH, Ward CM. Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. <i>Semin Thromb Hemost</i> 2013;39(1):25–32
Neil A. Goldenberg	2011	Bernard TJ, Armstrong-Wells J, Goldenberg NA. The institution-based prospective inception cohort study: design, implementation, and quality assurance in pediatric thrombosis and stroke research. <i>Semin Thromb Hemost</i> 2013;39(1):10–14
Vivien Chen	2011	Chen VM. Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange. <i>Semin Thromb Hemost</i> 2013;39(1):40–47
Joseph E. Italiano, Jr.	2011	Italiano JE Jr. Unraveling mechanisms that control platelet production. <i>Semin Thromb Hemost</i> 2013;39(1):15–24
Vivian Xiaoyan Du	2012/2013	Du VX, Huskens D, Maas C, Al Dieri R, de Groot PG, de Laat B. New insights into the role of erythrocytes in thrombus formation. <i>Semin Thromb Hemost</i> 2014;40(1):72–80
Andrew Yee	2012/2013	Yee A, Kretz CA. Von Willebrand factor: form for function. <i>Semin Thromb Hemost</i> 2014;40(1):17–27
Sarah O'Brien	2012/2013	O'Brien SH. Contraception-related venous thromboembolism in adolescents. <i>Semin Thromb Hemost</i> 2014;40(1):66–71
Veronica Flood	2012/2013	Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. <i>Semin Thromb Hemost</i> 2014;40(1):41–48
Julie Tange	2012/2013	Tange JI, Grill D, Koch CD, et al. Local verification and assignment of mean normal prothrombin time and International Sensitivity Index values across various instruments: recent experience and outcome from North America. <i>Semin Thromb Hemost</i> 2014;40(1):115–120
Kent Chapman	2012/2013	Chapman K, Yuen S. Therapy for thrombotic thrombocytopenia purpura: past, present, and future. <i>Semin Thromb Hemost</i> 2014;40(1):34–40
Andreas Tiede	2014	Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia a: limitations, consequences, and challenges. <i>Semin Thromb Hemost</i> 2014;40(7):803–811
Wendy Lim	2014	Lim W. Thrombotic risk in the antiphospholipid syndrome. <i>Semin Thromb Hemost</i> 2014;40(7):741–746
Susana Nobre Fernandes	2014	Fernandes S, Carvalho M, Lopes M, Araújo F. Impact of an individualized prophylaxis approach on young adults with severe hemophilia. <i>Semin Thromb Hemost</i> 2014;40(7):785–789
Maria Elisa Mancuso	2014	Mancuso ME, Fasulo MR. Thrombin generation assay as a laboratory monitoring tool during by-passing therapy in patients with hemophilia and inhibitors. <i>Semin Thromb Hemost</i> 2016;42(1):30–35
Coen Maas	2014	Tersteeg C, Fijnheer R, Deforche L, et al. Keeping von Willebrand factor under control: alternatives for ADAMTS13. <i>Semin Thromb Hemost</i> 2016;42(1):9–17
Riten Kumar	2014	Kumar R, Dunn A, Carcao M. Changing paradigm of hemophilia management: extended half-life factor concentrates and gene therapy. <i>Semin Thromb Hemost</i> 2016;42(1):18–29
Juraj Sokol	2015	Sokol J, Skerenova M, Jedinakova Z, et al. Progress in the understanding of sticky platelet syndrome. <i>Semin Thromb Hemost</i> 2017;43(1):8–13
Ljubica Jovanović	2015	Jovanovic L, Antonijevic N, Novakovic T, et al. Practical aspects of monitoring of antiplatelet therapy. <i>Semin Thromb Hemost</i> 2017;43(1):14–23
Lucia Stanciakova	2015	Stanciakova L, Dobrotova M, Jedinakova Z, et al. Monitoring of hemostasis and management of anticoagulant thromboprophylaxis in pregnant women with increased risk of fetal loss. <i>Semin Thromb Hemost</i> 2016;42(6):612–621
Tina Biss	2015	Biss TT. Venous thromboembolism in children: is it preventable? <i>Semin Thromb Hemost</i> 2016;42(6):603–611
Tobias Fuchs	2015	Jiménez-Alcázar M, Kim N, Fuchs TA. Circulating extracellular DNA: cause or consequence of thrombosis? <i>Semin Thromb Hemost</i> 2017;43(6):553–561

(Continued)

Table 2 (Continued)

Awardee	Year awarded	Publication arising
Jonathan M. Coutinho	2015	Silvis SM, Middeldorp S, Zuurbier SM, Cannegieter SC, Coutinho JM. Risk factors for cerebral venous thrombosis. <i>Semin Thromb Hemost</i> 2016;42(6):622–631
Soundarya Selvam	2016	Selvam S, James P. Angiodysplasia in von Willebrand disease: understanding the clinical and basic science. <i>Semin Thromb Hemost</i> 2017;43(6):572–580
Vincent Muczynski	2016	Muczynski V, Christophe OD, Denis CV, Lenting PJ. Emerging therapeutic strategies in the treatment of hemophilia A. <i>Semin Thromb Hemost</i> 2017;43(6):581–590
Karen Schreiber	2016	Schreiber K, Breen K, Cohen H, et al. Hydroxychloroquine to improve pregnancy outcome in women with Antiphospholipid Antibodies (HYPATIA) Protocol: a multi-national randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. <i>Semin Thromb Hemost</i> 2017;43(6):562–571
Jasmine Wee Ting Tay	2016	Tay J, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating microRNA as thrombosis sentinels: caveats and considerations. <i>Semin Thromb Hemost</i> 2018. doi: 10.1055/s-0037-1606568
Adi J. Klil-Drori	2016	Klil-Drori AJ, Tagalakakis V. Direct oral anticoagulants in end-stage renal disease. <i>Semin Thromb Hemost</i> 2018. DOI: https://doi.org/10.1055/s-0037-1621715 .
Lindsey A. George	2016	Submission still pending
Ivar van Asten	2017	van Asten I, Schutgens REG, Urbanus RT. Towards flow cytometry based platelet function diagnostics. <i>Semin Thromb Hemost</i> 2018.

the “most popular” 2012–2013 list.²² Also motivating is that a few of the Young Investigator awardees were also included as authors on other contributions to *Seminars in Thrombosis & Hemostasis* that were also listed in these most popular listings, including another 2014 Most Popular award winner.⁵¹

These findings act to validate the Young Investigator award process, and I look forward to seeing their careers continue to develop. These findings also suggest that future Young Investigator awardees have very high bars established, and I wish them the best of luck to exceed the precedence set by earlier awardees.

I would like as always to congratulate the current Young Investigator awardees for their awards, and will also take the opportunity to thank previous Young Investigator awardees for their contributions; these have obviously been well received by readers of this journal. I look forward to reading, and monitoring the future popularity, of the contributions from the latest group of Young Investigators!

References

- Favaloro EJ. Editorial. Welcome to a special issue of *Seminars in Thrombosis and Hemostasis*—The Closing Issue for 2008. *Semin Thromb Hemost* 2008;34:693–696
- Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930–2008). *Semin Thromb Hemost* 2008;34(08):703–707
- Favaloro EJ. Editorial. Welcome to the first issue of *Seminars in Thrombosis and Hemostasis* for 2009. *Semin Thromb Hemost* 2009;35:1–2
- Favaloro EJ. Editorial. Winners of the inaugural Eberhard F. Mammen award for most popular article. *Semin Thromb Hemost* 2009; 35:587–590
- Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award Winners. *Semin Thromb Hemost* 2010;36:469–470
- Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008–2009. *Semin Thromb Hemost* 2010;36(07):685–692
- Favaloro EJ. 2011 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2011;37(05):431–439
- Favaloro EJ. 2012 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2012;38:425–432
- Favaloro EJ. Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2013;39:567–574
- Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2014;40(04): 407–412
- Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. *Semin Thromb Hemost* 2014; 40(07):718–723
- Favaloro EJ. 2015 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2015;41 (07):673–679
- Favaloro EJ. 2015 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. *Semin Thromb Hemost* 2015; 41(08):809–815
- Favaloro EJ. 2016 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2016;42 (04):325–330
- Favaloro EJ. 2016 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. *Semin Thromb Hemost* 2017; 43(03):235–241
- Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2017;43 (04):357–363
- Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. *Semin Thromb Hemost* 2011;37(08):885–896
- Pels SG. Current therapies in primary immune thrombocytopenia. *Semin Thromb Hemost* 2011;37(06):621–630

- 19 Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. *Semin Thromb Hemost* 2012;38(01):31–37
- 20 Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. *Semin Thromb Hemost* 2012;38(01):64–78
- 21 Szántó T, Joutsu-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. *Semin Thromb Hemost* 2012;38(01):55–63
- 22 Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. *Semin Thromb Hemost* 2012;38(01):23–30
- 23 Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. *Semin Thromb Hemost* 2012;38(01):102–113
- 24 Lacroix R, Dignat-George F. Microparticles: new protagonists in pericellular and intravascular proteolysis. *Semin Thromb Hemost* 2013;39(01):33–39
- 25 McEwen BJ, Morel-Kopp MC, Chen W, Tofler GH, Ward CM. Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. *Semin Thromb Hemost* 2013;39(01):25–32
- 26 Bernard TJ, Armstrong-Wells J, Goldenberg NA. The institution-based prospective inception cohort study: design, implementation, and quality assurance in pediatric thrombosis and stroke research. *Semin Thromb Hemost* 2013;39(01):10–14
- 27 Italiano JE Jr. Unraveling mechanisms that control platelet production. *Semin Thromb Hemost* 2013;39(01):15–24
- 28 Du VX, Huskens D, Maas C, Al Dieri R, de Groot PG, de Laat B. New insights into the role of erythrocytes in thrombus formation. *Semin Thromb Hemost* 2014;40(01):72–80
- 29 Yee A, Kretz CA. Von Willebrand factor: form for function. *Semin Thromb Hemost* 2014;40(01):17–27
- 30 O'Brien SH. Contraception-related venous thromboembolism in adolescents. *Semin Thromb Hemost* 2014;40(01):66–71
- 31 Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. *Semin Thromb Hemost* 2014;40(01):41–48
- 32 Tange JI, Grill D, Koch CD, et al. Local verification and assignment of mean normal prothrombin time and International Sensitivity Index values across various instruments: recent experience and outcome from North America. *Semin Thromb Hemost* 2014;40(01):115–120
- 33 Chapman K, Yuen S. Therapy for thrombotic thrombocytopenia purpura: past, present, and future. *Semin Thromb Hemost* 2014;40(01):34–40
- 34 Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. *Semin Thromb Hemost* 2014;40(07):803–811
- 35 Lim W. Thrombotic risk in the antiphospholipid syndrome. *Semin Thromb Hemost* 2014;40(07):741–746
- 36 Fernandes S, Carvalho M, Lopes M, Araújo F. Impact of an individualized prophylaxis approach on young adults with severe hemophilia. *Semin Thromb Hemost* 2014;40(07):785–789
- 37 Mancuso ME, Fasulo MR. Thrombin generation assay as a laboratory monitoring tool during by-passing therapy in patients with hemophilia and inhibitors. *Semin Thromb Hemost* 2016;42(01):30–35
- 38 Tersteeg C, Fijnheer R, Pasterkamp G, et al. Keeping von Willebrand factor under control: alternatives for ADAMTS13. *Semin Thromb Hemost* 2016;42(01):9–17
- 39 Kumar R, Dunn A, Carcao M. Changing paradigm of hemophilia management: extended half-life factor concentrates and gene therapy. *Semin Thromb Hemost* 2016;42(01):18–29
- 40 Sokol J, Skerenova M, Jedinakova Z, et al. Progress in the understanding of sticky platelet syndrome. *Semin Thromb Hemost* 2017;43(01):8–13
- 41 Jovanovic L, Antonijevic N, Novakovic T, et al. Practical aspects of monitoring of antiplatelet therapy. *Semin Thromb Hemost* 2017;43(01):14–23
- 42 Stanciakova L, Dobrotova M, Jedinakova Z, et al. Monitoring of hemostasis and management of anticoagulant thromboprophylaxis in pregnant women with increased risk of fetal loss. *Semin Thromb Hemost* 2016;42(06):612–621
- 43 Biss TT. Venous thromboembolism in children: is it preventable? *Semin Thromb Hemost* 2016;42(06):603–611
- 44 Jiménez-Alcázar M, Kim N, Fuchs TA. Circulating extracellular DNA – cause or consequence of thrombosis? *Semin Thromb Hemost* 2017;43(06):553–561
- 45 Silvis SM, Middeldorp S, Zurbier SM, Cannegieter SC, Coutinho JM. Risk factors for cerebral venous thrombosis. *Semin Thromb Hemost* 2016;42(06):622–631
- 46 Selvam S, James P. Angiodysplasia in von Willebrand disease: understanding the clinical and basic science. *Semin Thromb Hemost* 2017;43(06):572–580
- 47 Muczynski V, Christophe OD, Denis CV, Lenting PJ. Emerging therapeutic strategies in the treatment of hemophilia A. *Semin Thromb Hemost* 2017;43(06):581–590
- 48 Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. *Semin Thromb Hemost* 2017;43(06):562–571
- 49 Tay J, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating microRNA as thrombosis sentinels: caveats and considerations. *Semin Thromb Hemost* 2018. Doi: 10.1055/s-0037-1606568
- 50 Klil-Drori AJ, Tagalakos V. Direct oral anticoagulants in end-stage renal disease. *Semin Thromb Hemost* 2018. Doi: <https://doi.org/10.1055/s-0037-1621715>
- 51 Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. *Semin Thromb Hemost* 2012;38(01):47–54